drugset / Trial / NCT03692767
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
SequentialOpen-labelTreatment
Summary
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
Timeline
- Start
- 2019-03
- Primary completion
- 2020-11
- Completion
- 2021-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD22 CAR NK Cells | Cell therapy | 50000 cells/kg | — |
| Subject | Anti-CD22 CAR NK Cells | Cell therapy | 600000 cells/kg | — |